Net prices of new antiobesity medications
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | Inmaculada Hernandez, Sean D. Sullivan |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
Nutritional considerations with antiobesity medications
por: Jaime P. Almandoz, et al.
Publicado: (2024)
por: Jaime P. Almandoz, et al.
Publicado: (2024)
Response to “Nutritional considerations with antiobesity medications”
por: Shaminie J. Athinarayanan
Publicado: (2024)
por: Shaminie J. Athinarayanan
Publicado: (2024)
Response to “Nutritional considerations with antiobesity medications”
por: Gabriela de Souza Bett, et al.
Publicado: (2024)
por: Gabriela de Souza Bett, et al.
Publicado: (2024)
Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications
por: Jamy D. Ard, et al.
Publicado: (2024)
por: Jamy D. Ard, et al.
Publicado: (2024)
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)
por: Jason M. Samuels, et al.
Publicado: (2024)
Meta‐analysis and machine learning reveal the antiobesity effects of melatonin on obese rodents
por: Yuying Li, et al.
Publicado: (2024)
por: Yuying Li, et al.
Publicado: (2024)
Managing the new wave of weight loss medication in general practice: A qualitative study
por: Pernille Andreassen, et al.
Publicado: (2024)
por: Pernille Andreassen, et al.
Publicado: (2024)
Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fills
por: Hamlet Gasoyan, et al.
Publicado: (2024)
por: Hamlet Gasoyan, et al.
Publicado: (2024)
Mindful eating and its relationship with body mass index, binge eating, anxiety and negative affect
por: Sheila Pintado-Cucarella
Publicado: (2016)
por: Sheila Pintado-Cucarella
Publicado: (2016)
Antiobesity medications in active‐duty military personnel
por: Brandon M. Roberts, et al.
Publicado: (2024)
por: Brandon M. Roberts, et al.
Publicado: (2024)
The association between weight loss medications and cardiovascular complications
por: Onur Baser, et al.
Publicado: (2024)
por: Onur Baser, et al.
Publicado: (2024)
Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
por: Calvin C. Wu, et al.
Publicado: (2025)
por: Calvin C. Wu, et al.
Publicado: (2025)
The vices and virtues of medical models of obesity
por: Jonathan Sholl, et al.
Publicado: (2024)
por: Jonathan Sholl, et al.
Publicado: (2024)
Obesity and postpartum hospital use among individuals without additional medical comorbidities
por: Kimberly B. Glazer, et al.
Publicado: (2024)
por: Kimberly B. Glazer, et al.
Publicado: (2024)
Weight management medications for chronic use in 37 veterans affairs medical centers—A medication use evaluation
por: Samantha Walczuk, et al.
Publicado: (2024)
por: Samantha Walczuk, et al.
Publicado: (2024)
Measurement and evaluation of community engagement in complex, chronic medical conditions: HIV and obesity as exemplar conditions
por: Andrew D. Brown, et al.
Publicado: (2025)
por: Andrew D. Brown, et al.
Publicado: (2025)
Determinants of adherence to obesity medication: A narrative review
por: Arya M. Sharma, et al.
Publicado: (2025)
por: Arya M. Sharma, et al.
Publicado: (2025)
Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study
por: Lee M. Kaplan, et al.
Publicado: (2025)
por: Lee M. Kaplan, et al.
Publicado: (2025)
Primary care perspectives on prescribing anti‐obesity medication for adolescents
por: Rutha Chivate, et al.
Publicado: (2024)
por: Rutha Chivate, et al.
Publicado: (2024)
The effects of anti‐obesity medications on bone metabolism: A critical appraisal
por: Athanasios D. Anastasilakis, et al.
Publicado: (2025)
por: Athanasios D. Anastasilakis, et al.
Publicado: (2025)
Evaluation of prescription medication changes following sleeve gastrectomy surgery
por: Gina Arena, et al.
Publicado: (2024)
por: Gina Arena, et al.
Publicado: (2024)
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover
por: Bo Liu, et al.
Publicado: (2024)
por: Bo Liu, et al.
Publicado: (2024)
Enfoque de la obesidad infantil desde la pediatría
por: Erika F. Hurtado-López
Publicado: (2014)
por: Erika F. Hurtado-López
Publicado: (2014)
Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
por: Shanshan Hu, et al.
Publicado: (2024)
por: Shanshan Hu, et al.
Publicado: (2024)
Incretin mimetics for weight loss forgive nonadherence
por: Anıl Cengiz, et al.
Publicado: (2025)
por: Anıl Cengiz, et al.
Publicado: (2025)
Correction to “Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time”
Publicado: (2024)
Publicado: (2024)
Ethnic differences in weight loss during a clinical obesity management program
por: Jennifer Linchee Kuk, et al.
Publicado: (2025)
por: Jennifer Linchee Kuk, et al.
Publicado: (2025)
The association of weight loss from anti‐obesity medications or bariatric surgery and apnea‐hypopnea index in obstructive sleep apnea
por: Brian W. Locke, et al.
Publicado: (2024)
por: Brian W. Locke, et al.
Publicado: (2024)
Associations of BMI, sleep quality, and sleep duration trajectories with new‐onset diabetes mellitus in the elderly
por: Shanshan Li, et al.
Publicado: (2025)
por: Shanshan Li, et al.
Publicado: (2025)
What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review
por: Kate Maslin, et al.
Publicado: (2024)
por: Kate Maslin, et al.
Publicado: (2024)
Comparative safety of glucose‐lowering medications on depression in adults with type 2 diabetes
por: Stephanie A. Hooker, et al.
Publicado: (2026)
por: Stephanie A. Hooker, et al.
Publicado: (2026)
Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
por: Juan Wang, et al.
Publicado: (2025)
por: Juan Wang, et al.
Publicado: (2025)
Four‐year follow‐up of weight loss maintenance using electronic medical record data: The PROPEL trial
por: Peter T. Katzmarzyk, et al.
Publicado: (2024)
por: Peter T. Katzmarzyk, et al.
Publicado: (2024)
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN
por: Deborah B. Horn, et al.
Publicado: (2025)
por: Deborah B. Horn, et al.
Publicado: (2025)
Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis
por: Jun Wang, et al.
Publicado: (2025)
por: Jun Wang, et al.
Publicado: (2025)
The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review
por: Sean Wharton, et al.
Publicado: (2024)
por: Sean Wharton, et al.
Publicado: (2024)
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study
por: Crystal M. Y. Lee, et al.
Publicado: (2025)
por: Crystal M. Y. Lee, et al.
Publicado: (2025)
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
por: Sean Wharton, et al.
Publicado: (2024)
por: Sean Wharton, et al.
Publicado: (2024)
Weight status of children and adolescents with autism spectrum disorder: A cross‐sectional analysis of primary care electronic medical records and linked health administrative datasets in Ontario, Canada
por: Laura M. Kinlin, et al.
Publicado: (2025)
por: Laura M. Kinlin, et al.
Publicado: (2025)
The association of motivational factors with weight loss and treatment time in a publicly funded weight management clinic
por: Amir Yazdanparast, et al.
Publicado: (2025)
por: Amir Yazdanparast, et al.
Publicado: (2025)
Ejemplares similares
-
Nutritional considerations with antiobesity medications
por: Jaime P. Almandoz, et al.
Publicado: (2024) -
Response to “Nutritional considerations with antiobesity medications”
por: Shaminie J. Athinarayanan
Publicado: (2024) -
Response to “Nutritional considerations with antiobesity medications”
por: Gabriela de Souza Bett, et al.
Publicado: (2024) -
Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications
por: Jamy D. Ard, et al.
Publicado: (2024) -
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)